Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Pediatr ; 2023: 8618245, 2023.
Article in English | MEDLINE | ID: mdl-38094904

ABSTRACT

Oseltamivir is a neuraminidase inhibitor used to treat acute influenza A or B in adult and pediatric patients. Adverse reactions are usually mild. Here, we report novel side effects associated with oseltamivir. The patient was an 11-year-old girl who developed lower lip cheilitis and stomatitis, after taking oseltamivir. Her symptoms and signs resolved within 36 h of oseltamivir discontinuation. She has clinically fully recovered and has remained well.

2.
Cureus ; 15(8): e43002, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37671213

ABSTRACT

The antipsychotic olanzapine is used increasingly to treat various psychiatric illnesses. Accidental olanzapine overdose is uncommon among children. Here, we report a case of a child presenting with an unexplained coma. Accidental ingestion of olanzapine (20 mg) was confirmed by measurement of drug concentrations in both serum and plasma.

3.
Hum Genet ; 120(5): 733-5, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17024364

ABSTRACT

In order to test the hypothesis that polymorphisms of the Marfan syndrome gene (FBN1) might affect the stature (height) of normal individuals, we genotyped three exonic SNPs on 428 males, 219 with tall stature (>2 SD) and 209 with normal stature (within +/-1 SD). One of the SNPs, rs8033037, in exon 15 showed a significant correlation (P = 0.0061) with the adult height, suggesting that FBN1 is one of the 'stature genes' of normal individuals.


Subject(s)
Body Height/genetics , Growth Disorders/genetics , Microfilament Proteins/genetics , Polymorphism, Single Nucleotide , Exons , Fibrillin-1 , Fibrillins , Gene Frequency , Genetic Predisposition to Disease , Genotype , Humans , Male , Mutation , Odds Ratio
4.
Clin Pediatr Endocrinol ; 15(2): 61-4, 2006.
Article in English | MEDLINE | ID: mdl-24790322

ABSTRACT

FGFR3 (fibroblast growth factor receptor 3) is a gene responsible for the most common form of osteodysplasia, achondroplasia, which results in extreme short stature. An allelic disorder, hypochondroplasia, however, presents with a much milder phenotype and is sometimes indistinguishable from idiopathic short stature. In this study, in order to test the possibility of the mildest end of hypochondroplasia being labeled as idiopathic short stature and the possibility of polymorphism of FGFR3 acting as one of the stature genes of normal individuals, we examined the prevalence of sequence alterations of the FGFR3 gene among individuals diagnosed clinically with idiopathic short stature. Sequencing analysis of all exons of the FGFR3 gene on 54 individuals with idiopathic short stature did not reveal any sequence variations related to the stature of the individuals. These results suggest that hidden hypochondroplasia among idiopathic short stature individuals is not a common occurrence and the contribution of polymorphism of the FGFR3 gene as a determinant of stature in normal individuals is small if any.

5.
J Clin Endocrinol Metab ; 89(6): 2905-8, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15181075

ABSTRACT

Mutations in the gene coding for hepatocyte nuclear factor-1beta (HNF-1beta) have been known to cause a form of maturity-onset diabetes of the young (MODY5), which is usually characterized by dominantly inherited adolescence-onset diabetes mellitus associated with renal cysts. This report, however, describes recurrence of a novel missense mutation in the HNF-1beta gene, S148W (C443G), in two sibs, one with neonatal diabetes mellitus and the other with neonatal polycystic, dysplastic kidneys leading to early renal failure. The former patient had only a few small renal cysts with normal renal functions, and the latter had only a transient episode of hyperglycemia, which resolved spontaneously. Interestingly, both parents were clinically unaffected, and PCR restriction fragment length polymorphism analysis showed that the mother was a low-level mosaic of normal and mutant HNF-1beta, which suggested that the recurrence was caused by germline mosaicism. This is the first report of permanent neonatal diabetes mellitus caused by a mutation of the HNF-1beta gene as well as the first report of germline mosaicism of this gene. In addition, the two cases described here show that additional factors, genetic or environmental, can have a significant influence on the phenotypic expression of HNF-1beta mutations.


Subject(s)
DNA-Binding Proteins/genetics , Diabetes Mellitus, Type 2/genetics , Germ-Line Mutation , Infant, Newborn, Diseases/genetics , Polycystic Kidney Diseases/genetics , Transcription Factors/genetics , Child , Child, Preschool , DNA Mutational Analysis , Diabetes Mellitus, Type 2/complications , Female , Genotype , Hepatocyte Nuclear Factor 1-beta , Humans , Infant, Newborn , Male , Mosaicism , Mutation, Missense , Phenotype , Polycystic Kidney Diseases/complications
6.
Clin Endocrinol (Oxf) ; 60(5): 608-12, 2004 May.
Article in English | MEDLINE | ID: mdl-15104564

ABSTRACT

OBJECTIVE: For patients with GH and gonadotrophin deficiency, adult height and sexual maturation are important not only for their physical but also psychological status. GH therapy is usually initiated soon after diagnosis but the differences in the age for initiation of therapy have not been previously examined. In this study, we assessed the influence of timing of initiation of GH therapy on adult height and the time of initiation of pubertal induction. DESIGN, PATIENTS AND MEASUREMENTS: Height-related data from 16 short children (13 boys and three girls) with GH and gonadotrophin deficiency who reached adult height after 10.9 +/- 2.3 years of GH therapy were analysed retrospectively. RESULTS: Adult height (0.00 +/- 0.69 SD) improved remarkably compared to height SDS at the start of GH therapy (-3.75 +/- 0.94 SD). The age at which GH therapy was started ranged from 3.2 to 12.0 years, but we found that such a difference in age did not affect adult height. However, an earlier start of GH therapy allowed earlier pubertal induction without loss of height potential. CONCLUSIONS: Earlier initiation of GH therapy is not required for normalization of adult height in patients with GH and gonadotrophin deficiency but it makes earlier pubertal induction possible, which is important for quality of life.


Subject(s)
Growth Disorders/drug therapy , Hormone Replacement Therapy , Human Growth Hormone/administration & dosage , Human Growth Hormone/deficiency , Pituitary Hormones/deficiency , Puberty/drug effects , Age Factors , Body Height/drug effects , Child , Child, Preschool , Female , Humans , Male , Recombinant Proteins/administration & dosage , Retrospective Studies
7.
Am J Med Genet ; 111(2): 134-9, 2002 Aug 01.
Article in English | MEDLINE | ID: mdl-12210339

ABSTRACT

The parental origin of the X chromosome of 45,X females has been the subject of many studies, and most of them have shown that the majority (60-80%) of the X chromosomes are maternal in origin. However, studies on the parental origin of normal X chromosomes are relatively limited for Turner syndrome (TS) females with sex chromosome aberrations. In this study, we used PCR-based typing of highly polymorphic markers and an assay of methylation status of the androgen receptor gene to determine the parental origin of normal X chromosomes in 50 unbiased TS females with a variety of karyotypes. Our results showed a higher paternal meiotic error rate leading to the generation of abnormal sex chromosomes, especially in the case of del(Xp) and abnormal Y chromosomes. Isochromosome Xq and ring/marker X chromosomes, on the other hand, were equally likely the result of both maternal and paternal meiotic errors. A thorough review of previous results, together with our data suggests, that the majority of TS karyotype are caused by paternal meiotic errors that generate abnormal sex chromosomes, and that most 45,X cells are generated by mitotic loss of these abnormal sex chromosomes, resulting in maternal X dominance in these cells.


Subject(s)
Chromosomes, Human, X/genetics , Receptors, Androgen/genetics , Sex Chromosome Aberrations , Turner Syndrome/genetics , Chromosomes, Human, Y/genetics , DNA Methylation , DNA Primers/chemistry , Female , Genetic Markers/genetics , Heterozygote , Humans , Karyotyping , Male , Microsatellite Repeats , Mosaicism , Polymerase Chain Reaction , Polymorphism, Genetic , Restriction Mapping
8.
Hum Genet ; 111(2): 161-5, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12189489

ABSTRACT

Propionic acidemia [MIM 606054] is a form of organic acidemia caused by genetic deficiency of propionyl-CoA carboxylase (PCC) and characterized by attacks of severe metabolic acidemia and hyperammonemia beginning in the neonatal period or in early infancy. There are, however, patients who have higher PCC activities and present later with unusual symptoms, such as mild mental retardation or extrapyramidal symptoms, sometimes even without metabolic acidosis. Through the neonatal screening of more than 130,000 Japanese newborns we detected a frequency of patients with propionic acidemia more than ten times higher than previously reported, most of them with milder phenotypes. The mutational spectrum was quite different from that of patients with the severe form and there was a common mutation (Y435C) in the beta subunit of the PCC gene (PCCB). Since patients with the mild form could present with unusual symptoms and therefore could easily remain unrecognized, it is important to identify those patients and clarify their natural history. Molecularly, one of the mutations (A1288C) caused an unusual pattern of multiple exon skipping and another unidentified mutation lead to the absence of mRNA. Taking into consideration previous findings regarding PCCB mutations, it appears that this gene is particularly prone to posttranscriptional modifications such as missense mediated exon skipping, mRNA decay, or rapid product degradation.


Subject(s)
Amino Acid Metabolism, Inborn Errors/epidemiology , Amino Acid Metabolism, Inborn Errors/genetics , Carboxy-Lyases/genetics , Carnitine/analogs & derivatives , Mutation , Propionates/blood , Adolescent , Adult , Amino Acid Metabolism, Inborn Errors/enzymology , Carboxy-Lyases/metabolism , Carnitine/blood , Child, Preschool , Citrates/urine , DNA Mutational Analysis , DNA Primers/chemistry , Exons , Humans , Infant , Japan/epidemiology , Methylmalonyl-CoA Decarboxylase , Polymerase Chain Reaction , Polymorphism, Single-Stranded Conformational , Prevalence , RNA, Messenger/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...